Cardiol Therapeutics Announces Clinical Steering Committee for Phase 2 International Trial in Acute Myocarditis Using CardiolRx(TM) 100
Cardiol Therapeutics Inc. is pleased to announce the formation of the Clinical Steering Committee for a Phase 2 international trial.
US Patent Office Approves Graphene 3D Patent of the Process for Synthesizing Trifluoroketones
Graphene 3D Lab Inc. is pleased to announce the US Patent Office has approved the issuance of the "Process for...
Talga Resources and BillerudKorsnas Sign Joint Agreement
Talga will be integrating its graphene-based material into BillerudKorsnas packaging products, replacing plastic materials.
Graphene 3D Lab Inc. Closes Oversubscribed Private Placement and Raises $212,000
Graphene 3D Lab Inc. is announcing that the Company has now closed an oversubscribed private placement for gross proceeds of...
Cardiol Therapeutics Announces Completion of Manufacturing Scale-up for Commercialization of CardiolRx(TM)100
Cardiol Therapeutics Inc., announces that it has completed the manufacturing scale-up for commercialization of its CardiolRx™100 CBD formulation.
Quantum Materials Leveraging Blockchain Platform for Counterfeit Solutions
Quantum Materials is combining nanotechnology and blockchain for counterfeit purposes, a first of its kind according to the company.
Cardiol Therapeutics to Webcast Live at VirtualInvestorConferences.com on September 12th
Cardiol Therapeutics Inc. (TSX:CRDL, OTCQX:CRTPF) President & CEO David Elsley will present live at the KCSA Cannabis Investor Conference on...